Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ... Annals of oncology 28, iv1-iv21, 2017 | 1695 | 2017 |
Diverse epigenetic strategies interact to control epidermal differentiation KW Mulder, X Wang, C Escriu, Y Ito, RF Schwarz, J Gillis, G Sirokmany, ... Nature cell biology 14 (7), 753-763, 2012 | 169 | 2012 |
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response A Haragan, JK Field, MPA Davies, C Escriu, A Gruver, JR Gosney Lung Cancer 134, 79-84, 2019 | 128 | 2019 |
ESMO Guidelines Committee Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ... Ann Oncol 28 (4), iv1-iv21, 2017 | 97 | 2017 |
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA M Tsuboi, W Weder, C Escriu, C Blakely, J He, S Dacic, Y Yatabe, L Zeng, ... Future Oncology 17 (31), 4045-4055, 2021 | 92 | 2021 |
Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste Ann Oncol 28 (suppl 4), 1-21, 2017 | 41 | 2017 |
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance LS Schwartzberg, H Horinouchi, D Chan, S Chernilo, ML Tsai, D Isla, ... NPJ precision oncology 4 (1), 15, 2020 | 26 | 2020 |
A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer AY Warren, CE Massie, K Watt, K Luko, F Orafidiya, LA Selth, ... Oncogene 38 (7), 1136-1150, 2019 | 23 | 2019 |
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG) S Popat, HA Jung, SY Lee, MJ Hochmair, SH Lee, C Escriu, MK Lee, ... Lung Cancer 162, 9-15, 2021 | 21 | 2021 |
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the … J Lester, C Escriu, S Khan, E Hudson, T Mansy, A Conn, S Chan, ... BMC cancer 21 (1), 515, 2021 | 20 | 2021 |
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker … GL Banna, O Cantale, S Muthuramalingam, J Cave, C Comins, ... International Immunopharmacology 110, 108985, 2022 | 17 | 2022 |
Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis RA De Mello, C Escriu, P Castelo-Branco, PL Cabral, G Mountzios, ... Oncotarget 9 (14), 11805, 2018 | 10 | 2018 |
A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM). PD Nathan, E Marshall, CT Smith, M Bickerstaff, C Escriu, M Marples, ... Journal of Clinical Oncology 30 (15_suppl), 8523-8523, 2012 | 10 | 2012 |
P03. 02 Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA M Tsuboi, W Weder, C Escriu, C Blakely, J He, S Dacic, Y Yatabe, L Zeng, ... Journal of Thoracic Oncology 16 (3), S258, 2021 | 9 | 2021 |
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the … M Sallam, H Wong, C Escriu BMC Pulmonary Medicine 19, 1-8, 2019 | 9 | 2019 |
Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis CS Gillespie, MA Mustafa, GE Richardson, AM Alam, KS Lee, DM Hughes, ... Journal of Thoracic Oncology, 2023 | 7 | 2023 |
The effects of GCSF primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy: a Sub-analysis … S Anpalakhan, P Huddar, R Behrouzi, A Signori, J Cave, C Comins, ... International Journal of Molecular Sciences 24 (2), 1746, 2023 | 6 | 2023 |
Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer C Escriu, JK Field Journal of Thoracic Disease 8 (9), 2357, 2016 | 5 | 2016 |
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis S Anpalakhan, P Huddar, R Behrouzi, A Signori, J Cave, C Comins, ... Frontiers in Oncology 13, 1163768, 2023 | 3 | 2023 |
Treatment beyond four cycles of first line platinum and etoposide chemotherapy in real-life patients with stage IV small cell lung cancer: A retrospective study of the … M Sallam, H Wong, C Escriu Annals of Oncology 29, viii598, 2018 | 2 | 2018 |